DSM moves into sterile clinical trial manufacturing

Published: 3-Jan-2007
Ingredients Research & Development


DSM Pharmaceuticals has completed an expansion to its sterile parenteral manufacturing facility in Greenville, NC, adding a clinical trial material manufacturing suite.

The new suite is capable of manufacturing large and small molecule liquid and lyophilized products for PI-III clinical trials.

Terry Novak, chief marketing officer, DSM Pharmaceuticals said the development would enable customers with sterile products in development to start with DSM in clinical trial manufacturing and stay with them through commercial manufacturing".

DSM Pharmaceuticals Inc is a business unit of DSM Pharmaceutical Products
and this latest service is supported by its existing services such as, QA Audits, Regulatory Support, Lyophilization Cycle development.

See more

You may also like

You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Formulation meets function: addressing palatability in drug development (part I)

Read more
Patient adherence to treatment regimens is inextricably linked to the palatability of medications, with consequences that can be far more serious than simply leaving a bad taste in one’s mouth

Trending Articles

  1. Douglas Pharmaceuticals sets new benchmark for capsule quality with CI Precision Partnership delivers compliance confidence, efficiency gains and reduced waste
  2. Servier acquires potential treatment for Fragile X syndrome KER-0193, a novel, orally bioavailable small molecule, was granted orphan drug and rare paediatric drug designation by the US FDA
  3. NICE recommends enfortumab vedotin with KEYTRUDA for adults in England/Wales with untreated metastatic urothelial cancer The results from the Phase III study EV-302/KN-A39 showed nearly a doubling of survival rates in patients compared with those who received platinum-based chemotherapy, which is the current standard of care in the UK
  4. FDA makes groundbreaking decision to waive clinical efficiency studies for monoclonal antibody biosimilars The University of Illinois secured the first-ever FDA acceptance to waive clinical efficiency studies (CESs) for the biological drugs
  5. Ryvu to support BioNTech’s clinical trials for cancer in Poland Ryvu will leverage its clinical network to streamline access to BioNTech’s investigational immunotherapies for Polish patients

Upcoming event

Enhancing probiotic stability through smarter formulation and packaging strategies

18 September 2025 | Virtual See all

You may also like

You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Formulation meets function: addressing palatability in drug development (part I)

Patient adherence to treatment regimens is inextricably linked to the palatability of medications, with consequences that can be far more serious than simply leaving a bad taste in one’s mouth
Ingredients

dsm-firmenich launches pharmaceutical taste solutions portfolio

The range aims to improve the taste and sensory experience of solid, liquid or semi-solid dosage forms
Ingredients

dsm-firmenich's CBtru demonstrates similar bioavailability to commercially available Epidiolex

The cannabidiol (CBD)-based drug product intermediate is absorbed into the bloodstream at a similar level compared with the only commercially approved CBD drug, Epidiolex
Ingredients

dsm-firmenich showcases excipient and sustainability solutions at CPHI Milan

The company will present its range of solutions designed to boost patient compliance, while also exhibiting its pharma-grade CBD ingredient
Ingredients

The roadmap to success in the cannabinoid drug development journey

The key to success in the development and registration of cannabinoid-based medicines hinges on choosing a GMP-certified high-purity active ingredient that is of natural origin and supported by regulatory documentation. Drug developers looking to take product development further still should also consider patient-centricity during formulation and strategies to boost the efficacy of cannabinoids by optimising their bioavailability profile
Ingredients

What role can CBD play to support mental health?

Talking to Dr Kevin Robinson (KSR), DSM’s Clinical Project Scientist, Mariana Coelho (MC), shares the latest scientific findings behind CBD and how it could help to support mental health and well-being on a global scale, especially as the demand for viable treatments continues to grow
Ingredients

CBD: the new frontier in medical science

Early stage drug development plays an important role in expanding treatment options that will support the health of patients globally. To create bespoke drug products, it is important to explore and understand the benefits of new actives emerging on the market, such as cannabidiol (CBD), explains Kelsey Achenbach, Senior Director, Pharma and Medical Nutrition at DSM
Subscribe now